Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 24, 2005 Charly Travers	Transkaryotic's Turnaround This biotech spotlights superb management creating shareholder value.
The Motley Fool December 1, 2009 Brian Orelli	Pfizer Takes In an Orphan on the Cheap Steal is a pretty accurate term for the price Pfizer paid for Protalix BioTherapeutics' taliglucerase alfa.
The Motley Fool June 21, 2005 Charly Travers	A Biotech Bargain Paying $1.6 billion for a robust pipeline and promising future may be a steal. Purchasing Transkaryotic's drug portfolio should pay off very soon for the specialty pharmaceutical Shire.
The Motley Fool March 3, 2011 Ryan McBride	With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players.
Pharmaceutical Executive March 1, 2006 Sara Calabro	Genzyme: The Price of Success Genzyme put patients first, and grew to become a multi-billion-dollar company. But empires don't survive on altruism.
The Motley Fool February 3, 2010 Brian Orelli	Pfizer's Hedge Pays Off FDA wants more data from Pfizer's partner, Protalix on their treatment for Gaucher disease.
The Motley Fool April 27, 2005 Charly Travers	Thanks for the Ride, Transkaryotic Selling was the right move, but it's hard to let go of stocks you like. Transkaryotic has certainly done very well for its shareholders.
The Motley Fool February 23, 2009 Brian Orelli	Genzyme Playing Defense The latest good news from this company won't help the top line much.
Chemistry World October 5, 2010 Andrew Turley	Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
The Motley Fool July 5, 2005 Bill Mann	This Merger Deserves Revisiting Transkaryotic agreed to $37 per share from Shire Pharmaceuticals -- but that was before the good news rolled in. These shares are worth 30% more today. The market knows it.
The Motley Fool July 7, 2010 Brian Orelli	That's Gotta Hurt: Recommending the Competition Supply constraints continue to plague Genzyme.
The Motley Fool February 25, 2011 Brian Orelli	Minor Delay, Major Missed Opportunity Protalix and Pfizer's Gaucher disease drug gets delayed.
The Motley Fool February 28, 2011 Brian Orelli	Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on.
The Motley Fool May 26, 2010 Brian Orelli	Is This 4,000-Liter Bioreactor Half-Full? Or half-empty? Only time will tell for Genzyme.
The Motley Fool February 17, 2010 Brian Orelli	Execute Well or You're Out Genzyme needs to show investors that it can rebuild.
The Motley Fool September 2, 2010 Brian Orelli	Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases.
The Motley Fool September 25, 2009 Brian Orelli	Genzyme's Good News. Finally! It's been awhile, hasn't it?
The Motley Fool July 12, 2006 Brian Lawler	Genzyme Continues to Deliver The biopharmaceutical company releases their second quarter earnings announcement. The stock is up sharply today, almost 8%, after Genzyme reported earnings of $0.68 a share.
The Motley Fool May 14, 2010 Ryan McBride	Genzyme in "Tough Spot" With Icahn Proxy Challenge Carl Icahn is pushing for change, but Genzyme's CEO has been pushing back.
Chemistry World February 17, 2011 Sarah Houlton	Sanofi to buy Genzyme in $20 billion deal Sanofi-Aventis has won its long-running battle for Genzyme, and is to acquire the US-based biotech for $74 ( 46) per share - about $20 billion in total - plus extra payments of up to $14 per share.
The Motley Fool March 2, 2004 David Nierengarten	Genzyme's Oncology Acquisitions The biotech gobbles up two smaller firms for their cancer treatment pipelines.
The Motley Fool February 18, 2005 John Bluis	Genzyme's Acquisitions Pay Off With some of this biotech's major decisions coming to fruition, shareholders can have more confidence that management can deliver on its promises.
The Motley Fool October 22, 2009 Brian Orelli	The Gift That Keeps on Giving Genzyme's manufacturing issues just won't go away. Four months after the company announced that it had shut down a manufacturing plant because of viral contamination, its stock is still dealing with the aftermath.
The Motley Fool November 18, 2008 Brian Orelli	Genzyme Grounded for Thanksgiving The biotech won't get a decision on Myozyme until February.
BusinessWeek April 22, 2010 Rob Waters	Gene Therapy Takes a Turn for the Better Researchers and investors are heartened by advances in gene therapy. Analysts say revenues are still several years off, however.
The Motley Fool June 3, 2004 Charly Travers	Small Drug Market, Big Hopes BioMarin is going to file for approval in the U.S. and Europe in the fourth quarter of this year after its succesful phase 3 trial of Aryplase. If the drug is approved, it would likely be on the market toward the end of 2005.
The Motley Fool August 5, 2010 Brian Orelli	Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still.
The Motley Fool April 24, 2008 Brian Lawler	FDA Stings Genzyme Earnings A nasty surprise hurts the drug developer's first quarter results.
The Motley Fool July 26, 2010 Ryan McBride	How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis
The Motley Fool September 23, 2010 Ryan McBride	Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault.
The Motley Fool July 23, 2009 Brian Orelli	This Too Shall Pass ... Like a Kidney Stone Demand outstrips supply? Boo-hoo. Lowered guidance because a company can't make enough to keep up with demand. Example: Genzyme
The Motley Fool October 4, 2010 Ryan McBride	Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share.
The Motley Fool October 12, 2006 Brian Lawler	Genzyme Runs a Tight Ship Revenues are up at the biopharmaceutical company, but shares dropped in morning trading.
The Motley Fool April 16, 2004 Charly Travers	Genzyme's Minor Disappointment The latest sales figures for Genzyme's newest drug, Aldurazyme, show that a potential growth-driving drug may be stalling out.
The Motley Fool February 11, 2010 Brian Orelli	A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects.
The Motley Fool December 30, 2004 Charly Travers	Genzyme Enters Cancer Arena The approval of a new drug is a long-term opportunity for the biotech giant.
The Motley Fool July 25, 2005 Charly Travers	Transkaryotic Therapies: What's It Worth? U.K.-based Shire Pharmaceuticals has offered to buy Transkaryotic Therapies for $37 a share. Will shareholders be shortchanged?
The Motley Fool July 18, 2005 Stephen D. Simpson	Rare Diseases Mean Solid Growth for Genzyme Genzyme doesn't target well-known diseases, but then neither does the competition. Valuing these shares is a bit tricky.
The Motley Fool March 3, 2009 Brian Orelli	A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals.
The Motley Fool November 18, 2010 Brian Orelli	Genzyme: Slimmed Down, Gussied Up But will anyone buy it?
The Motley Fool April 20, 2011 Charly Travers	Are These the Rights You're Looking for? Consider the contingent value rights of these pharma stocks, which entitle the owner to receive cash payments if certain performance milestones are met in the future.
The Motley Fool December 10, 2008 Brian Orelli	A Painless Advisory Panel Meeting Genzyme might be getting a Christmas present from the Food and Drug Administration. An FDA advisory panel unanimously recommended approval for Genzyme's osteoarthritis pain drug Synvisc-One.
Managed Care June 2004 Thomas Morrow	Laronidase Opens Door To Treat Other Rare Disorders The release of alpha-L-iduronidase also demonstrates the wave of future treatments for many other mucopolysaccharidosis (MPS) diseases.
The Motley Fool July 27, 2007 Brian Lawler	Jumpstarting Genzyme A great quarter for Genzyme. All three of its top products had double-digit percentage sales gains; operating margins are up too.
The Motley Fool November 19, 2009 Brian Orelli	This Stock Is a Train Wreck Genzyme's string of missteps has investors nervous.
The Motley Fool April 20, 2006 John Bluis	Investors Jump Ship at Genzyme Clearly, Genzyme continues to invest in its business for the long term. That's the type of approach that can create a steady stream of market-beating returns for investors if they're willing to trust management.
The Motley Fool October 21, 2010 Brian Orelli	Genzyme: Nice Quarter, Still Too Expensive After its train wreck of manufacturing problems, Genzyme seems like it's getting the cars back on track.
The Motley Fool July 23, 2007 Brian Lawler	Acquisitive Ways Paying Off for Genzyme A recently acquired drug yields positive study results. Genzyme investors, take note.
The Motley Fool October 28, 2010 Brian Orelli	This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37.